Sarah Mian
1, Yogesh Acharya
1, Ranjan Dahal
2*1 Avalon University School of Medicine, Curacao, Netherlands Antilles
2 Saint Peter’s University Hospital, New Jersey, USA
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disorder
that impacts approximately 12 million worldwide. It is characterized by bilateral kidney
enlargement and cystic growth. Hypertension (HTN) is a focal point in the management
of ADPKD and is linked to a faster progression to end stage renal disease. Current novel
therapies have proven to reduce the progression of renal damage. The ideal goal is to minimize
risk through preventative studies and pharmacology to further increase life expectancy
and quality. The purpose of this article is to highlight the importance of blood pressure
management in ADPKD and review current literature to determine the most effective
preventative pharmacotherapy.
Implication for health policy/practice/research/medical education:
1. Hypertension (HTN) is an important risk factor for progressive renal and extra-renal complications in adult polycystic kidney
disease (ADPKD).
2. Ambulatory blood pressure monitoring is important as complications like left ventricular hypertrophy (LVH) can manifest
even before the diagnosis of HTN.
3. HTN, if not treated early, will potentially lead to faster glomerular filtration rate (GFR) decline and end stage renal disease.
4. Although no overall benefit of one antihypertensive over other is established to prevent decline in GFR, angiotensin-converting
enzyme inhibitor (ACE-I)/ angiotensin receptor blocker (ARB) is recommended at present.
5. There is a strong need for standardized guidelines for management of HTN in ADPKD.
Please cite this paper as: Mian S, Acharya Y, Dahal R. Hypertension in adult polycystic kidney disease: a narrative review.
J Renal Inj Prev. 2019;8(2):122-126. doi: 10.15171/jrip.2019.23.